Genmab A/S (LON: 0MGB)
London
· Delayed Price · Currency is GBP · Price in DKK 1,544.07
+18.34 (1.20%)
At close: Jan 22, 2025
Genmab Revenue
Genmab had revenue of 5.54B DKK in the quarter ending September 30, 2024, with 17.57% growth. This brings the company's revenue in the last twelve months to 19.84B, up 17.75% year-over-year. In the year 2023, Genmab had annual revenue of 16.47B with 13.57% growth.
Revenue (ttm)
19.84B DKK
Revenue Growth
+17.75%
P/S Ratio
n/a
Revenue / Employee
9.00M DKK
Employees
2,204
Market Cap
10.87B GBP
Revenue Chart
* This company reports financials in DKK.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 16.47B | 1.97B | 13.57% |
| Dec 31, 2022 | 14.51B | 6.09B | 72.33% |
| Dec 31, 2021 | 8.42B | -1.69B | -16.75% |
| Dec 31, 2020 | 10.11B | 4.75B | 88.43% |
| Dec 31, 2019 | 5.37B | 2.34B | 77.39% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Shell | 221.41B |
| AstraZeneca | 38.20B |
| HSBC Holdings | 43.25B |
| Unilever | 51.12B |
| Rio Tinto Group | 42.87B |
| RELX PLC | 9.30B |
| BP p.l.c. | 144.69B |
| British American Tobacco p.l.c. | 26.18B |
Genmab News
- 19 days ago - Genmab to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 5 weeks ago - Genmab A/S: Circling Back On This Complicated Story - Seeking Alpha
- 6 weeks ago - Genmab to Hold 2024 R&D Update and ASH Data Review Meeting - GlobeNewsWire
- 6 weeks ago - Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) - Business Wire
- 6 weeks ago - Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis - Business Wire
- 6 weeks ago - Genmab Is Too Attractive To Ignore - Seeking Alpha
- 6 weeks ago - Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) - Business Wire
- 7 weeks ago - Capital Increase in Genmab as a Result of Employee Warrant Exercise - GlobeNewsWire